Atara Biotherapeutics, Inc. - Common Stock (NQ: ATRA )
8.590
-0.130
(-1.49%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
All News about Atara Biotherapeutics, Inc. - Common Stock
![](https://mms.businesswire.com/media/20220519005615/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_10984.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/earnings_image_2119.jpeg)
![](/images/schema-image-default.png)
![](https://mms.businesswire.com/media/20220504006179/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20220505006060/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/ep_us_feature_image_2739.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20220429005657/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20220428005344/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20220421006031/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20220404005914/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20220404006039/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://cdn.benzinga.com/files/images/story/2012/red-blood-cell-gc6575ac93_1920_2.jpg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20220401005459/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20220315006164/en/1390741/4/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics to Host EBV and MS Day
March 15, 2022
Via Business Wire
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3462.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3550.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_402.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_130.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3443.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/ep_us_feature_image_1057.jpeg)
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
February 24, 2022
Exposures
COVID-19
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_3582.png)
![](https://mms.businesswire.com/media/20220217006012/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
February 18, 2022
Via Business Wire
![](https://mms.businesswire.com/media/20220215006185/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20220207005829/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](/images/schema-image-default.png)
![](https://mms.businesswire.com/media/20220126006000/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
![](https://mms.businesswire.com/media/20220122005025/en/792504/4/Atara-Bio1_logo_300x185-1.jpg)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free